Sebastiaan de Jong new Brand President Etos
Zaandam, the Netherlands, June 3, 2021 - Sebastiaan de Jong (47) has been appointed Brand President of drugstore chain Etos, effective July 1st, 2021. De Jong started his career at Ahold Delhaize 23 years ago and is currently working as Head of Procurement of Ahold Delhaize Europe & Indonesia. He will report to Wouter Kolk, CEO Ahold Delhaize Europe & Indonesia.
De Jong has gained extensive commercial and operational experience at Ahold Delhaize. After studying economics, he started as a management trainee at Ahold in 1998, starting with his first job at Etos. He continued his career in various buying, marketing & format and merchandising positions including a position as SVP Commerce in the Czech Republic for the Ahold Delhaize-brand Albert. In 2017 he became VP store operation at Albert Heijn. In 2018 Sebastiaan was appointed Chief Commercial Officer at Intergamma. At this DIY market leader in the Benelux he gained experience in the field of omnichannel organizational development. In early 2021 Sebastiaan returned to Ahold Delhaize in the role of Head of Procurement at Ahold Delhaize Europe & Indonesia, where he launched and led the European procurement initiative.
Wouter Kolk, CEO Ahold Delhaize Europe & Indonesia: “With the appointment of Sebastiaan, the Etos team gains a teamplayer with extensive retail experience, in the Netherlands and internationally. In his various roles, Sebastiaan has demonstrated to be an inclusive leader, focused on team collaboration and set on bringing out the best in everyone. Etos has a long history in qualitative and innovative personal care products and in advising customers. The drugstore brand is a familiar and trusted face in the streets of The Netherlands. Sebastiaan will be focused on further shaping the strong Etos strategy with the team. I am convinced that he will make an excellent new Brand President for the company.”
Sebastiaan de Jong: “Etos is a wonderful brand, rooted in society and with a loyal customer base. I personally relate strongly to the mission to help our customers feel good every day and I am very much looking forward to leading the further development of Etos together with the team."
De Jong will start in his role at Etos as of July 1st and will be double hatted, fulfilling the procurement role, until Fall 2021.
Dutch drugstore chain Etos, founded in 1919, has long been a trusted expert on what customers (72% of the Dutch population) are increasingly looking for, in stores and at home. Etos owns, among others, health websites gezondheidsplein.nl and ziekenhuis.nl. The company is thus the largest provider of online health and wellness information in the Netherlands. In its 550 stores, Etos employs 5,400 associates, of which 2400 are certified (assistant) chemists. Etos has been voted the best drugstore in the Netherlands seven times.
This communication includes forward-looking statements. All statements other than statements of historical facts may be forward-looking statements. Words and expressions such as will, be, further, strategy, until Fall 2021 or other similar words or expressions are typically used to identify forward-looking statements.
Forward-looking statements are subject to risks, uncertainties and other factors that are difficult to predict and that may cause actual results of Koninklijke Ahold Delhaize N.V. (the “Company”) to differ materially from future results expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risk factors set forth in the Company’s public filings and other disclosures. Forward-looking statements reflect the current views of the Company’s management and assumptions based on information currently available to the Company’s management. Forward-looking statements speak only as of the date they are made and the Company does not assume any obligation to update such statements, except as required by law.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Ceylon Graphite Announces Licence for Vein Graphite and Graphene Technologies14.6.2021 13:15:00 CEST | Press release
VANCOUVER, British Columbia, June 14, 2021 (GLOBE NEWSWIRE) -- Ceylon Graphite Corp. (“Ceylon Graphite”) (TSX-V: CYL) (OTC: CYLYF) (FSE: CCY) is pleased to announce that it has acquired an exclusive global licence from Cambridge Advanced Materials & Innovation (“CAMI”). The licence pertains to a method of producing high quality few-layer graphene (“FLG”) and derivatives by exfoliation of high grade vein graphite produced by Ceylon Graphite (“The Technology”). This is a low-energy process which results in high-yield, few layer graphene products. This industrial process is already fully designed for large volume production, and is scalable, with modules added as demand increases. Upon completion of the licence agreement, Ceylon Graphite has gained full access to all intellectual property surrounding The Technology and know-how. Use of Ceylon’s high-grade feedstock material- vein graphite - leads to minimal to nil industrial waste during the production of graphene. The combination of uniq
GBT’s Voxelotor is First Sickle Cell Disease Treatment to Receive Promising Innovative Medicine (PIM) Designation in the UK14.6.2021 13:00:00 CEST | Press release
SOUTH SAN FRANCISCO, Calif. and LONDON, June 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments for underserved patient communities, announced today that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom has granted a Promising Innovative Medicine (PIM) designation for voxelotor for the potential treatment of hemolytic anemia in adults and adolescent patients 12 years of age and older with sickle cell disease (SCD). Following a review by the MHRA, PIM designations are given to promising treatments that are likely to offer a major advantage for patients and are an early indication that the treatment is a promising candidate for the Early Access to Medicines Scheme (EAMS). For the MHRA to grant a PIM designation, the product must meet each of the following three criteria: The condition should be life-threatening or
Incap Corporation: INCAP CONTINUES TO RAMP UP ITS FACTORIES IN INDIA, LOCK-DOWN EXTENDED UNTIL 21 JUNE 2021. INCAP’S PREVIOUSLY ANNOUNCED OUTLOOK FOR 2021 REMAINS UNCHANGED.14.6.2021 10:45:00 CEST | Press release
Incap Corporation 14 June 2021 at 11:45 a.m. (EEST) Stock Exchange Release Insider information INCAPCONTINUES TO RAMP UP ITS FACTORIES IN INDIA, LOCK-DOWN EXTENDED UNTIL 21 JUNE 2021. INCAP’S PREVIOUSLY ANNOUNCED OUTLOOK FOR 2021 REMAINS UNCHANGED. Incap announced on 10 May 2021 that it had temporarily closed down its factories in Tumkur until 24 May 2021. On 24 May 2021, Incap announced that the lock-down had been extended until 7 June 2021 and that it had been granted a permission for partial operation of its factories. Currently, the lock-down in Karnataka has been extended until 21 June 2021. Incap’s factories in India continue to operate according to the government guidelines and Incap is prepared to resume full operations once the restrictions are removed. The closure and the partial operations of the factories in India do not have an impact on the company’s outlook for 2021 published on 21 April 2021. Incap’s previously announced outlook for 2021: Incap estimates that its revenu
2022 PAN EUROPEAN LAUNCH OF OKUMA REELS, RODS AND COMBOS BY RAPALA VMC CORPORATION SUPPORTED BY MASSIVE MARKETING CAMPAIGN14.6.2021 10:30:00 CEST | Press release
2022 PAN EUROPEAN LAUNCH OF OKUMA REELS, RODS AND COMBOS BY RAPALA VMC CORPORATION SUPPORTED BY MASSIVE MARKETING CAMPAIGN Rapala VMC Corporation (“Rapala VMC”) announced on January 27, 2021 the acquisition of Okuma European and Russian trademarks and associated intangible assets. Rapala VMC is now pleased to announce that the largescale launch of Okuma reels, rods and combos in Europe and Russia will occur January 1, 2022. Svendsen Sport A/S (“Svendsen“) and Okuma Fishing Tackle Co Ltd (“Okuma”) have recently agreed that Okuma’s long term exclusive distribution agreement with Svendsen covering Denmark, Norway, Sweden, Iceland, UK, Ireland, France, Germany, The Netherlands, Luxembourg, Austria, Belgium, Czech Republic, Hungary, Poland and Russia (“Svendsen Territory”) will terminate effective December 31, 2021 and that Svendsen’s rights to collect pre-orders terminates September 15, 2021. To facilitate a smooth transition, Rapala VMC has agreed to acquire Svendsen’s inventories of Okum
Progress on Brunel share buyback program 202114.6.2021 10:30:00 CEST | Press release
Amsterdam, 14 June 2021 – Brunel International N.V. (Brunel; BRNL), reports the transaction details for the period 7 June 2021 through 11 June 2021 related to its share buyback program announced on 1 June 2021 for an amount up to EUR 1,977,000, and started on 3 June 2021 in order to meet obligations under its performance share plan for senior management (excluding Board of Directors). Detailed information including all individual transactions can be found on https://www.brunelinternational.net/en/share-buyback-program. DateTotal shares repurchasedAverage purchase priceTotal consideration07/06/202111,305€ 11.4980€ 129,984.8908/06/202113,004€ 11.3393€ 147,456.2609/06/202114,164€ 11.2713€ 159,646.6910/06/202113,034€ 11.3668€ 148,154.8711/06/20217,434€ 11.4107€ 84,827.14Total58,941€ 11.3685€ 670,069.85 This press release contains inside information as meant in clause 7 of the Market Abuse Regulation. Attachment Press Release Share Buyback 2021 progress
Scandinavian Tobacco Group A/S: Transactions in connection with share buy-back programme14.6.2021 09:35:04 CEST | Press release
Company Announcement No. 31/2021 Copenhagen, 14 June 2021 Transactions in connection with share buy-back programme On 10 March 2021, Scandinavian Tobacco Group A/S (“STG”) announced that a share buy-back programme of an aggregated price of up to DKK 600 million was launched with the purpose to adjust the Company’s capital structure and meet obligations relating to the Group’s share-based incentive programme. The buy-back programme is executed in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. The share buy-back programme will end no later than 28 February 2022. The following transactions have been executed from 7 June to 11 June 2021: Number of sharesAverage purchase price, DKKTransaction value, DKKAccumulated, last announcement1,241,419154,300,854 7 June 202120,000131.172,623,400 8 June 202120,000130.372,607,494
bp går sammen med Aker og Statkraft om norsk havvindsatsing14.6.2021 08:30:00 CEST | Pressemelding
(Oslo, 14. juni 2021) bp har i dag besluttet å bli med Aker og Statkraft i et konsortium som vil søke konsesjon for utvikling av havvind i Norge. Partnerskapet – der bp, Statkraft og Aker Offshore Wind eier en tredjedel hver – vil aktivt søke konsesjon for å utvikle havvind i lisensområdet Sørlige Nordsjø II (SN2). Den gunstige plasseringen av SN2 gjør det mulig å levere kraft til flere omkringliggende markeder. Partnerne ser også på mulighetene for å levere fornybar kraft til elektrifisering av olje- og gassinstallasjoner. Konsortiet vil jobbe med lokale leverandører, bygge opp norsk industrikompetanse innen havvind og bidra til verdiskaping i det nordiske og europeiske kraftmarkedet. Partnerskapet kombinerer hvert av selskapenes sterke, tekniske ferdigheter og omfattende erfaring med energiprosjekter offshore som dekker hele verdikjeden fra prosjektutvikling til produksjon og levering av havbasert energi til markedet. bp har eierandeler i britisk og amerikansk havvind og mangeårig er